Drugs & Aging

, Volume 19, Issue 2, pp 85–100 | Cite as

Thalidomide in Cancer Treatment

A Potential Role in the Elderly?
  • Shufeng Zhou
  • Philip Kestell
  • Malcolm D. Tingle
  • James W. Paxton
Review Article

Abstract

There is increased interest in the treatment of cancer with thalidomide because of its antiangiogenic, immunomodulating and sedative effects. In animal models, the antitumour activity of thalidomide is dependent on the species, route of administration and coadministration of other drugs. For example, thalidomide has shown antitumour effects as a single agent in rabbits, but not in mice. In addition, the antitumour effects of the conventional cytotoxic drug cyclophosphamide and the tumour necrosis factor inducer 5,6-dimethylxanthenone-4-acetic acid (DMXAA) were found to be potentiated by thalidomide in mice bearing colon 38 adenocarcinoma tumours. Further studies have revealed that thalidomide upregulates intratumoral production of tumour necrosis factor-α 10-fold over that induced by DMXAA alone. Coadministration of thalidomide also significantly reduced the plasma clearance of DMXAA and cyclophosphamide. All these effects of thalidomide may contribute to the enhanced antitumour activity.

Recent clinical trials of thalidomide have indicated that it has minimal anticancer activity for most patients with solid tumours when used as a single agent, although it was well tolerated. However, improved responses have been reported in patients with multiple myeloma. Palliative effects of thalidomide on cancer-related symptoms have also been observed, especially for geriatric patients with prostate cancer. Thalidomide also eliminates the dose-limiting gastrointestinal toxic effects of irinotecan. There is preliminary evidence indicating that the clearance of thalidomide may be reduced in the elderly.

The exact role of thalidomide in the treatment of cancer and cancer cachexia in the elderly remains to be elucidated. However, it may have some value as part of a multimodality anticancer therapy, rather than as a single agent.

Notes

Acknowledgements

The authors gratefully appreciate the support of the Maurice and Phyllis Paykel Trust, the University of Auckland Research Fund and the Auckland Medical Research Foundation.

References

  1. 1.
    Lenz W. Thalidomide and congenital abnormalities [editorial]. Lancet 1962; I: 45CrossRefGoogle Scholar
  2. 2.
    McBride WG. Thalidomide and congenital abnormalities. Lancet 1968; II: 1358Google Scholar
  3. 3.
    D’Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91: 4082–5PubMedCrossRefGoogle Scholar
  4. 4.
    Figg WD, Reed E, Green S, et al. Thalidomide: a prodrug that inhibits angiogenesis. In: Teicher BA, editor. Antiangiogenic agents in cancer therapy. Totowa (NJ): Humana Press, 1999: 407–22Google Scholar
  5. 5.
    Yuichi H. Novel biological response modifiers derived from thalidomide. Curr Med Chem 1998; 5: 163–78Google Scholar
  6. 6.
    Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med 2000; 108: 487–95PubMedCrossRefGoogle Scholar
  7. 7.
    Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs 2000; 60: 273–92PubMedCrossRefGoogle Scholar
  8. 8.
    Udagawa T, Verheul HMW, D’Amato RJ. Thalidomide and analogs. In: Teicher BA, editor. Antiangiogenic agents in cancer therapy. Totowa (NJ): Humana Press, 1999: 263–74Google Scholar
  9. 9.
    Ordi-Ros J, Cortes F, Cucurull E, et al. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol 2000; 27: 1429–33PubMedGoogle Scholar
  10. 10.
    Sampaio EP, Kaplan G, Miranda A. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodusum leprosum. J Infect Dis 1993; 168: 408–14PubMedCrossRefGoogle Scholar
  11. 11.
    Walchner M, Meurer M, Plewig G, et al. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol 2000; 39: 383–8PubMedCrossRefGoogle Scholar
  12. 12.
    Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis: the thalidomide experience. J Rheumatol 1989; 16: 158–63PubMedGoogle Scholar
  13. 13.
    Lenardo TM, Calabrese LH. The role of thalidomide in the treatment of rheumatic disease. J Clin Rheumatol 2000; 6: 19–26PubMedCrossRefGoogle Scholar
  14. 14.
    Gori A, Rossi MC, Marchetti G, et al. Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease. AIDS 2000; 14: 1859–61PubMedCrossRefGoogle Scholar
  15. 15.
    Larsson H. Treatment of severe colitis in Behcet’s syndrome with thalidomide (CG-217). J Intern Med 1990; 228: 405–7PubMedCrossRefGoogle Scholar
  16. 16.
    Postema PT, den-Haan P, van-Hagen PM, et al. Treatment of colitis in Behcet’s disease with thalidomide. Eur J Gastroenterol Hepatol 1996; 8: 929–31PubMedGoogle Scholar
  17. 17.
    Russell AI, Lawson WA, Haskard DO. Potential new therapeutic options in Behcet’s syndrome. Biodrugs 2001; 15: 25–35PubMedCrossRefGoogle Scholar
  18. 18.
    Koc S, Leisenring W, Flowers MED, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000; 96: 3995–6PubMedGoogle Scholar
  19. 19.
    Vogelsang GB, Farmer ER, Hess AD. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326: 1055–8PubMedCrossRefGoogle Scholar
  20. 20.
    Haslett P, Hempstead M, Seidman C, et al. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 1997; 13: 1047–54PubMedCrossRefGoogle Scholar
  21. 21.
    Makonkawkeyoon S, Limson-Pobre RN, Moreira AL, et al. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1993; 90: 5974–8PubMedCrossRefGoogle Scholar
  22. 22.
    Sharpstone D, Rowbottom A, Francis N, et al. Thalidomide: a novel therapy for microsporidiosis. Gastroenterology 1997; 112: 1823–9PubMedCrossRefGoogle Scholar
  23. 23.
    Facchini S, Candusso M, Martelossi S, et al. Efficacy of long term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J Pediatr Gastroenterol Nutr 2001; 32: 178–81PubMedCrossRefGoogle Scholar
  24. 24.
    Ginsburg PM, Hanan I, Ehrenpreis ED. Treatment of severe esophageal Crohn’s disease with thalidomide. Am J Gastroenterol 2001; 96: 1305–6PubMedCrossRefGoogle Scholar
  25. 25.
    Sandborn WJ. Therapy for Crohn disease. Curr Opin Gastroenterol 2000; 16: 318–23PubMedCrossRefGoogle Scholar
  26. 26.
    Ryan J. Thalidomide treatment of oesophageal ulceration. Gut 2000; 47: 145CrossRefGoogle Scholar
  27. 27.
    Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32: 866–9PubMedCrossRefGoogle Scholar
  28. 28.
    Eriksson T, Bjorkman S, Roth B, et al. Enantiomers of thalidomide-blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality 1998; 10: 223–8PubMedCrossRefGoogle Scholar
  29. 29.
    Eriksson T, Bjorkman S, Roth B, et al. Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J Pharm Pharmacol 2000; 52: 807–17PubMedCrossRefGoogle Scholar
  30. 30.
    Hoglund P, Eriksson T, Bjorkman S. A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J Pharmacokinet Biopharm 1998; 26: 363–83PubMedGoogle Scholar
  31. 31.
    Wnendt S, Finkam M, Winter W, et al. Enantioselective inhibition f TNF-α release by thalidomide and thalidomide analogues. Chirality 1996; 8: 390–6PubMedCrossRefGoogle Scholar
  32. 32.
    Eriksson T, Bjorkman S, Roth B, et al. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 1995; 7: 44–52PubMedCrossRefGoogle Scholar
  33. 33.
    Baidas SM, Winer EP, Fleming GF, et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000; 18: 2710–7PubMedGoogle Scholar
  34. 34.
    Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent highgrade gliomas. J Clin Oncol 2000; 18: 708–15PubMedGoogle Scholar
  35. 35.
    Marx GM, McCowatt S, Boyle F, et al. Phase II study of thalidomide as an anti-angiogenic agent in the treatment of recurrent glioblastoma multiforme (GBM) [abstract]. Proc Annu Meet Am Soc Clin Oncol 2000; 19: 159aGoogle Scholar
  36. 36.
    Politi P, Reboredo G, Losso M, et al. Phase I trial of thalidomide in AIDS-related Kaposi sarcoma [abstract]. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 41aGoogle Scholar
  37. 37.
    Tseng JE, Glisson BS, Khuri FR, et al. Phase II trial of thalidomide in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck(SCHN) [abstract]. Proc Annu Meet Am Soc Clin Oncol 2000; 19: 471aGoogle Scholar
  38. 38.
    Mihich E, Fefer A. Biological response modifiers: subcommittee report. Bethesda (MD): National Cancer Institute, 1983Google Scholar
  39. 39.
    Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 1999; 58: 17–38PubMedCrossRefGoogle Scholar
  40. 40.
    Kerbel RS, Viloria-Petit A, Klement G, et al. ‘Accidental’ antiangiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000; 36: 1248–57PubMedCrossRefGoogle Scholar
  41. 41.
    Kruger EA, Reed E, Figg WD. Angiogenesis in health and disease: basic mechanisms and clinical applications. New York: Marcel Dekker, 2000Google Scholar
  42. 42.
    Nguyen M, Tran C, Barsky S, et al. Thalidomide and chemotherapy combination: preliminary results of preclinical and clinical studies. Int J Oncol 1997; 10: 965–9PubMedGoogle Scholar
  43. 43.
    Chaplin DJ, Dougherty GJ. Tumor vasculature as a target for cancer therapy. Br J Cancer 1999; 80Suppl. 1: 57–64PubMedGoogle Scholar
  44. 44.
    Kerb RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21: 505–15CrossRefGoogle Scholar
  45. 45.
    Malonne H, Langer I, Kiss R, et al. Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors. Clin Exp Metast 1999; 17: 1–14CrossRefGoogle Scholar
  46. 46.
    Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249–57PubMedCrossRefGoogle Scholar
  47. 47.
    Eatock MM, Schatzlein A, Kaye SB. Tumor vasculature as a target for anticancer therapy. Cancer Treat Rev 2000; 26: 191–204PubMedCrossRefGoogle Scholar
  48. 48.
    Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52: 237–68PubMedGoogle Scholar
  49. 49.
    Hayes AJ, Li LY, Lippman ME. Antivascular therapy: a new approach to cancer treatment. BMJ 1999; 318: 853–6PubMedCrossRefGoogle Scholar
  50. 50.
    Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation which is species-dependent. Biochem Pharmacol 1998; 55: 1827–34PubMedCrossRefGoogle Scholar
  51. 51.
    Browe WL, Wilson WR, Baguley BC, et al. Suppression of serum tumor necrosis factor-α by thalidomide does not lead to reversal of tumor vascular collapse and anti-tumor activity of 5,6-dimethylxanthenone-4-acetic acid. Anticancer Res 1998; 18: 4409–13Google Scholar
  52. 52.
    Kenyon BM, Browne F, D’Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64: 971–8PubMedCrossRefGoogle Scholar
  53. 53.
    Kotoh T, Dhar DK, Masunaga R, et al. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery 1999; 125: 536–44PubMedCrossRefGoogle Scholar
  54. 54.
    Kruse FE, Joussen AM, Rohrschneider K, et al. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998; 236: 461–6PubMedCrossRefGoogle Scholar
  55. 55.
    Minchinton AI, Fryer KH, Wendt KR, et al. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996; 7: 339–43PubMedCrossRefGoogle Scholar
  56. 56.
    Eriksson T, Bjorkman S, Roth B, et al. Hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man. J Pharm Pharmacol 1998; 50: 1409–16PubMedCrossRefGoogle Scholar
  57. 57.
    Meyring M, Muhlenbrock C, Blaschke G. Investigation of the stereoselective in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis. Electrophoresis 2000; 21: 3270–9PubMedCrossRefGoogle Scholar
  58. 58.
    Meyring M, Strickmann D, Chankvetadze B, et al. Investigation of the in vitro biotransformation of R-(+)-thalidomide by HPLC, nano-HPLC, CEC and HPLC-APCI-MS. J Chromatogr (B) 1999; 723: 255–64CrossRefGoogle Scholar
  59. 59.
    Schumacher H, Blake DA, Gilette JR. Disposition of thalidomide in rabbits and rats. J Pharmacol Exp Ther 1968; 160: 201–11PubMedGoogle Scholar
  60. 60.
    Schumacher H, Smith RL, William RT. The metabolism of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol 1965; 25: 338–51Google Scholar
  61. 61.
    Teo SK, Sabourin PJ, O’Brien K, et al. Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen’s disease patients. J Biochem Mol Toxicol 2000; 14: 140–7PubMedCrossRefGoogle Scholar
  62. 62.
    Weinz C, Blaschke G. Investigation of the in vitro biotransformation and simultaneous separation of thalidomide and its neutral metabolites by capillary electrophoresis. J Chromatogr (B) 1995; 674: 287–92CrossRefGoogle Scholar
  63. 63.
    Gordon GB, Spielberg SP, Blake DA, et al. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc Natl Acad Sci U S A 1981; 78: 2545–8PubMedCrossRefGoogle Scholar
  64. 64.
    Ambrus JL, Toumbis CA, Karakousis CP, et al. Study of antiangiogenic agents with possible therapeutic applications in neoplastic disorders and macular degeneration. J Med 2000; 31: 278–82PubMedGoogle Scholar
  65. 65.
    Gnant MF, Turner EM, Alexander Jr H. Effects of hyperthermia and tumor necrosis factor on inflammatory cytokine secretion and procoagulant activity in endothelial cells. Cytokine 2000; 12: 339–47PubMedCrossRefGoogle Scholar
  66. 66.
    Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor α-dependent angiogenesis. Mol Cell Biol 1997; 17: 4015–23PubMedGoogle Scholar
  67. 67.
    Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996; 31: 213–21PubMedCrossRefGoogle Scholar
  68. 68.
    Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin avb3 for angiogenesis. Science 1994; 264: 569–71PubMedCrossRefGoogle Scholar
  69. 69.
    Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin avb3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157–64PubMedCrossRefGoogle Scholar
  70. 70.
    Eliceiri BP, Cheresh DA. The role of av integrins during an-giogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999; 103: 1227–30PubMedCrossRefGoogle Scholar
  71. 71.
    Varner JA. The role of vascular cell integrins α v ß3 and α v ß5 in angiogenesis. EXS 1997; 79: 361–90PubMedGoogle Scholar
  72. 72.
    Huizinga TWJ, Dijkmans BAC, Vandervelde EA, et al. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis 1996; 55: 833–6PubMedCrossRefGoogle Scholar
  73. 73.
    Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 1993; 77: 1675–80CrossRefGoogle Scholar
  74. 74.
    Rowland TL, Mchugh SM, Deighton J, et al. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology 1998; 40: 11–20PubMedCrossRefGoogle Scholar
  75. 75.
    Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991; 173: 699–703PubMedCrossRefGoogle Scholar
  76. 76.
    Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti TNF-α inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996; 81: 219–23PubMedCrossRefGoogle Scholar
  77. 77.
    Miyachi H, Azuma A, Hioki E, et al. Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-α production. Biochem Biophys Res Commun 1996; 224: 426–30PubMedCrossRefGoogle Scholar
  78. 78.
    Miyachi H, Azuma A, Hioki E, et al. Cell-type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-α production and its enantiodependence. Biochem Biophys Res Commun 1996; 226: 439–44PubMedCrossRefGoogle Scholar
  79. 79.
    Shannon EJ, Sandoval F. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-α by mononuclear cells. Immunopharmacol Immunotoxicol 1996; 18: 59–72PubMedCrossRefGoogle Scholar
  80. 80.
    Dunzendorfer S, Herold M, Wiedermann CJ. Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide. Immunopharmacology 1999; 43: 59–64PubMedCrossRefGoogle Scholar
  81. 81.
    Haslett PAJ, Klausner JD, Makonkawkeyoon S, et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses 1999; 15: 1169–79PubMedCrossRefGoogle Scholar
  82. 82.
    Moller DR, Wysocka M, Greenlee BM, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997; 159: 5157–61PubMedGoogle Scholar
  83. 83.
    Shannon E, Aseffa A, Pankey G, et al. Thalidomide’s ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood. Immunopharmacology 2000; 46: 175–9PubMedCrossRefGoogle Scholar
  84. 84.
    Shannon EJ, Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology 1995; 31: 109–16PubMedCrossRefGoogle Scholar
  85. 85.
    van Crevel R, Vonk AG, Netea MG, et al. Modulation of LPS-, HA- and M-tuberculosis-mediated cytokine production by pentoxifylline and thalidomide. Eur Cytokine Network 2000; 11: 574–9Google Scholar
  86. 86.
    Oliver SJ, Moreira A, Kaplan G. Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol 2000; 97: 109–20PubMedCrossRefGoogle Scholar
  87. 87.
    Meierhofer C, Dunzendorfer S, Wiedermann CJ. Theoretical basis for the activity of thalidomide. Biodrugs 2001; 15: 681–703PubMedCrossRefGoogle Scholar
  88. 88.
    Krown SE. Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr Opin Oncol 2001; 13: 374–81PubMedCrossRefGoogle Scholar
  89. 89.
    Verbon A, Juffermans NP, Speelman P, et al. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete γ interferon in healthy humans. Antimicrob Agents Chemother 2000; 44: 2286–90PubMedCrossRefGoogle Scholar
  90. 90.
    Shannon EJ, Sandoval F, Krahenbuhl JL. Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-α. Immunopharmacology 1997; 36: 9–15PubMedCrossRefGoogle Scholar
  91. 91.
    Karrow NA, McCay JA, Brown RD, et al. Thalidomide stimulates splenic IgM antibody response and cytotoxic Tlymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice. Toxicol Appl Pharmacol 2000; 165: 237–44PubMedCrossRefGoogle Scholar
  92. 92.
    Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256: 42–9PubMedCrossRefGoogle Scholar
  93. 93.
    Makin G, Hickman JA. Apoptosis and cancer chemotherapy. Cell Tissue Res 2000; 301: 143–52PubMedCrossRefGoogle Scholar
  94. 94.
    Aseffa A, Dietrich MA, Shannon EJ. Effects of thalidomide on apoptosis of lymphocytes and neutrophils. Immunopharmacol Immunotoxicol 1997; 19: 313–26PubMedCrossRefGoogle Scholar
  95. 95.
    Guckian M, Dransfield I, Hay P, et al. Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro. Clin Exp Immunol 2000; 121: 472–9PubMedCrossRefGoogle Scholar
  96. 96.
    Guinan P, Shaw M, Mirochnik Y, et al. Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model. Methods Find Exp Clin Pharmacol 1998; 20: 739–42PubMedGoogle Scholar
  97. 97.
    Lotem J, Sachs L. Cytokines as suppressors of apoptosis. Apoptosis 1999; 4: 187–96PubMedCrossRefGoogle Scholar
  98. 98.
    Somers GF. Pharmacological properties of thalidomide (α-phthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol 1960; 15: 111–6Google Scholar
  99. 99.
    Frederickson RC, Slater IH, Dusenberry WE, et al. A comparison of thalidomide and pentobarbitol: new methods for identifying novel hypnotic drugs. J Pharmacol Exp Ther 1977; 203: 240–51PubMedGoogle Scholar
  100. 100.
    Ochonisky S, Verroust J, Bastji-Garin S, et al. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994; 130: 66–9PubMedCrossRefGoogle Scholar
  101. 101.
    Gutman M, Szold A, Ravid A, et al. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res 1996; 16: 3673–7PubMedGoogle Scholar
  102. 102.
    Myoung H, Hong SD, Kim YY, et al. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett 2001; 163: 191–200PubMedCrossRefGoogle Scholar
  103. 103.
    Smith C, Friednash M, Nguyen C, et al. Failure of thalidomide as an anti-angiogenesis factor in a murine melanoma model. J Invest Dermatol 1996; 106: 845Google Scholar
  104. 104.
    Bach A, Bichel J, Hejgaard JJ. Studies on the possible antineoplastic effect of thalidomide. Acta Pathol Microbiol Scand 1963; 58–59: 491–9Google Scholar
  105. 105.
    DiPaolo JA. Thalidomide: influence on production of congenital abnormalities in mice and cancer chemotherapy. Fed Proc 1963; 22(II): 666Google Scholar
  106. 106.
    Paxton JW, Kestell P, Ching L-M, et al. Preliminary studies on the interaction between cyclophosphamide and thalidomide. Drug Metab Rev 2001; 33: 181Google Scholar
  107. 107.
    Baguley BC, Zhuang L, Kestell P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol Res 1997; 9: 550–60Google Scholar
  108. 108.
    Joseph WR, Cao Z, Mountjoy KG, et al. Stimulation of tumors to synthesize tumor necrosis factor-α in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 1999; 59: 633–8PubMedGoogle Scholar
  109. 109.
    Philpott M, Baguley BC, Ching L-M. Induction of tumor necrosis factor-α by single and repeated doses of the antitumor agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1995; 36: 143–8PubMedCrossRefGoogle Scholar
  110. 110.
    Thomsen LL, Ching L-M, Baguley BC. Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid. Cancer Res 1990; 50: 6966–70PubMedGoogle Scholar
  111. 111.
    Thomsen LL, Ching L-M, Zhuang L, et al. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 1991; 51: 77–81PubMedGoogle Scholar
  112. 112.
    Ching L-M, Browne WL, Tchernegovski R, et al. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumor agent 5,6-dimethylxanthenone-4-aceticacid: concomitant reduction of serum tumor necrosis factor-α and enhancement of anti-tumor activity. Br J Cancer 1998; 78: 336–43PubMedCrossRefGoogle Scholar
  113. 113.
    Ching L-M, Xu Z-F, Gummer BH, et al. Effect of thalidomide on tumor necrosis factor production and anti-tumor activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995; 72: 339–43PubMedCrossRefGoogle Scholar
  114. 114.
    Cao Z, Joseph WR, Browne WL, et al. Thalidomide increases both intra-tumoral tumor necrosis factor-α production and anti-tumor activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1999; 80: 716–23PubMedCrossRefGoogle Scholar
  115. 115.
    Kestell P, Zhao L, Ching L-M, et al. Modulation of the plasma pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid by thalidomide in mice. Cancer Chemother Pharmacol 2000; 46: 135–41PubMedCrossRefGoogle Scholar
  116. 116.
    Zhou SF, Paxton JW, Tingle MD, et al. In vitro and in vivo kinetic interactions of the anti-tumor agent 5,6-dimethy-xanthenone-4-acetic acid with thalidomide and diclofenac. Cancer Chemother Pharmacol 2001; 47: 319–26PubMedCrossRefGoogle Scholar
  117. 117.
    Pollard M. Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats. Cancer Lett 1996; 101: 21–4PubMedCrossRefGoogle Scholar
  118. 118.
    Verheul HMW, Panigrahy D, Yuan J, et al. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumor growth in rabbits. Br J Cancer 1999; 79: 114–8PubMedCrossRefGoogle Scholar
  119. 119.
    Kohler F, Ockenfels H. Teratogenic effect of N-phthalyl-DL-glutamic acid following intraperitoneal application in mice. Experientia 1970; 26: 1157–8PubMedCrossRefGoogle Scholar
  120. 120.
    Grabstald H, Golbey R. Clinical experience with thalidomide in patients with cancer. Clin Pharmacol Ther 1965; 6: 298–302PubMedGoogle Scholar
  121. 121.
    Olson KB, Hall TC, Horton J, et al. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clin Pharmacol Ther 1965; 6: 292–7PubMedGoogle Scholar
  122. 122.
    Long G, Vredenburgh J, Rizzieri DA, et al. Pilot trial of thalidomide post-autologous peripheral blood progenitor cell transplantation PBPC in patients with metastatic breast cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 181aGoogle Scholar
  123. 123.
    Eisen T, Boshoff C, Mak I, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 82: 812–7PubMedCrossRefGoogle Scholar
  124. 124.
    Figg WD, Bergan R, Brawley O, et al. Randomized phase II study of thalidomide in androgen-independent prostate cancer (AIPC) [abstract]. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 333aGoogle Scholar
  125. 125.
    Figg WD, Raje S, Bauer KS, et al. Pharmacokinetics of thalidomide in an elderly prostate cancer population. J Pharm Sci 1999; 88: 121–5PubMedCrossRefGoogle Scholar
  126. 126.
    Fife K, Howard MR, Gracie F, et al. Activity of thalidomide in AIDS-related Kaposi’s sarcoma and correlation with HHV8 titer. Int J STD AIDS 1998; 9: 751–5PubMedCrossRefGoogle Scholar
  127. 127.
    Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi’s sarcoma. J Clin Oncol 2000; 18: 2593–602PubMedGoogle Scholar
  128. 128.
    Yarchoan R. Therapy for Kaposi’s sarcoma: recent advances and experimental approaches. J AIDS 1999; 21Suppl. 1: S66–73Google Scholar
  129. 129.
    Glass J, Gruber ML, Nirenberg A. A phase I/II study of carboplatin and thalidomide in recurrent glioblastoma multiforme [abstract]. Proc Annu Meet Am Soc Clin Oncol 1999; 18: 144aGoogle Scholar
  130. 130.
    Alexanian R, Anderson KC, Barlogie B, et al. Thalidomide in hematologic malignancies: future directions. Semin Hematol 2000; 37Suppl. 3: 35–9CrossRefGoogle Scholar
  131. 131.
    Alexanian R, Weber DBS. Thalidomide for resistant and relapsing myeloma. Semin Hematol 2000; 37Suppl. 3: 22–5CrossRefGoogle Scholar
  132. 132.
    Anderson KC. Thalidomide: therapeutic potential in hematologic malignancies. Semin Hematol 2000; 37Suppl. 3: 1–4CrossRefGoogle Scholar
  133. 133.
    Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001; 86: 404–8PubMedGoogle Scholar
  134. 134.
    Juliusson G, Celsing F, Turesson I, et al. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000; 109: 89–96PubMedCrossRefGoogle Scholar
  135. 135.
    Kishi Y, Oki Y, Machida U. Thalidomide in multiple myeloma. N Engl J Med 2000; 342: 975PubMedCrossRefGoogle Scholar
  136. 136.
    Kneller A, Raanani P, Hardan I, et al. Therapy with thalidomide in refractory multiple myeloma patients: the revival of an old drug. Br J Haematol 2000; 108: 391–3PubMedCrossRefGoogle Scholar
  137. 137.
    Larkin M. Low-dose thalidomide seems to be effective in multiple myeloma. Lancet 1999; 354: 925PubMedCrossRefGoogle Scholar
  138. 138.
    Larkin M. Thalidomide continues to look promising as an anticancer agent. Lancet 1999; 354: 1705CrossRefGoogle Scholar
  139. 139.
    Munshi NC, Desikan KR, Barlogie B. Clinical experience with thalidomide in multiple myeloma: phase II trial results in refractory disease and ongoing studies. Semin Hematol 2000; 37Suppl. 3: 15–21CrossRefGoogle Scholar
  140. 140.
    Palumbo A, Giaccone L, Bertola A, et al. Low-dosethalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86: 399–403PubMedGoogle Scholar
  141. 141.
    Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000; 75: 897–901PubMedCrossRefGoogle Scholar
  142. 142.
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–71PubMedCrossRefGoogle Scholar
  143. 143.
    Trojan A, Anagnostara A, Fost L. Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma. Swiss Med Weekly 2001; 131: 133Google Scholar
  144. 144.
    Zomas A, Anagnostopoulos N, Dimopoulos MA. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. Bone Marrow Transplant 2000; 25: 1319–20PubMedCrossRefGoogle Scholar
  145. 145.
    Govindarajan R, Heaton KM, Broadwater R, et al. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 2000; 356: 566–7PubMedCrossRefGoogle Scholar
  146. 146.
    Minor D, Elias L. Thalidomide treatment of metastatic renal cell carcinoma [abstract]. Proc Annu Meet Am Soc Clin Oncol 2000; 19: 352aGoogle Scholar
  147. 147.
    Patt YZ, Hassan MM, Lozano RD, et al. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000; 23: 319–21PubMedCrossRefGoogle Scholar
  148. 148.
    Merchant JJ, Hammes LC, Larson ML, et al. Pilot and safety trial of carboplatin, paclitaxel and thalidomide in advanced non-small cell lung cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol 2000; 19: 541aGoogle Scholar
  149. 149.
    Thomas DA. Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders. Semin Hematol 2000; 37 1 Suppl. 3: 26–34CrossRefGoogle Scholar
  150. 150.
    Nelson KA. The cancer anorexia-cachexia syndrome. Semin Oncol 2000; 27: 64–8PubMedGoogle Scholar
  151. 151.
    Argiles JM, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev 1999; 19: 223–48PubMedCrossRefGoogle Scholar
  152. 152.
    Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 1999; 59: 4493–501PubMedGoogle Scholar
  153. 153.
    Yeh SS, Schuster MW. Geriatric cachexia: the role of cytokines. Am J Clin Nutr 1999; 70: 183–97PubMedGoogle Scholar
  154. 154.
    Haslett PAJ. Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 1998; 25Suppl. 6: 53–7PubMedGoogle Scholar
  155. 155.
    Bruera E, Neumann CM, Pituskin E, et al. Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncol 1999; 10: 857–9PubMedCrossRefGoogle Scholar
  156. 156.
    Calder K, Bruera E. Thalidomide for night sweats in patients with advanced cancer [letter]. Palliat Med 2000; 14: 77–8PubMedCrossRefGoogle Scholar
  157. 157.
    Deaner P. Thalidomide for distressing night sweats in advanced malignant disease [letter]. Palliat Med 1998; 12: 208–9PubMedCrossRefGoogle Scholar
  158. 158.
    Chen TL, Vogelsang GB, Petty BG, et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos 1989; 17: 402–5PubMedGoogle Scholar
  159. 159.
    Piscitelli SC, Figg WD, Hahn B, et al. Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1997; 41: 2797–9PubMedGoogle Scholar
  160. 160.
    Reist M, Carrupt PA, Francotte E, et al. Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem Res Toxicol 1998; 11: 1521–8PubMedCrossRefGoogle Scholar
  161. 161.
    Jonsson NA. Chemical structure and teratogenic properties. 3. A review of available data on structure-activity relationships and mechanism of action of thalidomide analogues. Acta Pharm Suecic 1972; 9: 521–42Google Scholar
  162. 162.
    Corral LG, Haslett PAJ, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999; 163: 380–6PubMedGoogle Scholar
  163. 163.
    Shah JH, Swartz GM, Papathanassiu AE, et al. Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: Potent inhibitors of tumor metastasis. J Med Chem 1999; 42: 3014–7PubMedCrossRefGoogle Scholar
  164. 164.
    Mantovani G, Maccio A, Lai P, et al. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 1998; 25Suppl. 6: 45–52PubMedGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Shufeng Zhou
    • 1
  • Philip Kestell
    • 2
  • Malcolm D. Tingle
    • 1
  • James W. Paxton
    • 1
  1. 1.Division of Pharmacology and Clinical Pharmacology, School of Medicine, Faculty of Medical and Health SciencesThe University of AucklandAucklandNew Zealand
  2. 2.Auckland Cancer Society Research CentreThe University of AucklandAucklandNew Zealand

Personalised recommendations